Michael Blackton has worked for 30 years in the pharmaceutical industry in leadership positions at Eli Lilly, IDEC, Millennium, BioMarin, and Inhale Therapeutics. Currently, Michael is VP Quality at Adaptimmune LLC.
A volunteer at PDA since the 1990s, Michael has been a member of the PDA Board of Directors since 2018. He was presented with a Service Appreciation Award in 2020.
He has been a member of the Biopharmaceutical Advisory Board, and has contributed to several technical reports, including TR-60, Process Validation A Lifecycle Approach, TR 60-2 Oral Solid Dosage/Semi-Solid Dosage Forms, TR-61, Steam in Place, and TR-81 Cell Based Therapy Control Strategy.
Michael has helped to establish the ATMP focus at PDA, organizing multiple U.S.-based Cell and Gene Therapy conferences – a first for PDA. As part of his work advocating ATMPs, Michael co-created the Cell and Gene Therapy Interest Group and is currently the co-chair of the ATMP Advisory Board.
In addition to his PDA activities, Michael served on the Editorial Review Board for Cell and Gene Magazine and has presented at numerous conferences.
Michael holds a Bachelors in Biochemistry from The University of California San Diego, and an MBA specializing in Strategy, Finance, and Leadership from the NYU Stern School of Business.
- Michael Blackton, MBA